Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet

Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the presentation and publication of results from the company’s Phase 2b ixCELL-DCM clinical study of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
According to the news:

The data were presented today by Timothy Henry, M.D., at the Late-Breaking Clinical Trial Session and press conference at the American College of Cardiology’s (ACC) 65^th Annual Scientific Session and published in The Lancet.  Dr. Henry is director of cardiology at Cedars-Sinai Heart Institute, principal investigator of the study and co-author of the Lancet publication.

Dr. David Recker, Vericel’s chief medical officer commented:

The ixCELL-DCM study met its primary endpoint of demonstrating a reduction in the total number of all-cause deaths, cardiovascular hospitalizations, or unplanned outpatient and emergency department visits to treat acute decompensated heart failure during the 12 months following treatment with ixmyelocel-T compared to placebo. From a safety perspective, the incidence of adverse events, including serious adverse events, in patients treated with ixmyelocel-T was comparable to or lower than patients in the placebo group.  We are very excited about the results of this clinical trial and greatly appreciate the contributions of the patients, investigators and dedicated personnel who participated in this study.

Click here to view the full press release.